Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 5 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Caps

How do you think CORT will perform against the market?

Add Stock to CAPS Watchlist

All Players

91 Outperform
25 Underperform
 

All-Star Players

13 Outperform
5 Underperform
 

Wall Street

4 Outperform
1 Underperform
 

Top CORT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

vistacarolina (< 20)
Submitted March 31, 2017

Great Co. will see positive results.

zzlangerhans (99.85)
Submitted July 13, 2016

In medicine we generalists have a saying: When you only tool is a hammer, every problem becomes a nail. It refers to the propensity of specialists to interpret every problem through the lens of their specialty. If a patient comes in with syncope, the… More

CORT VS S&P 500 (SPY)

Fools bullish on CORT are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about CORT.

Recs

0
Member Avatar TMFBlacknGold (95.14) Submitted: 10/24/2018 1:18:48 PM : Outperform Start Price: $12.46 CORT Score: +27.62

From 8/10/2018:

"Corcept Therapeutics stock is down 30% since the beginning of 2018, which seems a bit harsh given the financial performance to date, even with the risk of generic competition hanging overhead. Korlym has single-handedly driven the business to profitability and allowed the company to self-fund pipeline development. That includes relacorilant, which could one day replace Korlym, avoid the risk of generic competition, and improve the lives of patients. If the drug candidate's development continues to impress, then investors may want to give this stock a closer look."

https://www.fool.com/investing/2018/08/10/heres-why-corcept-therapeutics-incorporated-fell-a.aspx

Recs

0
Member Avatar MarkBiotech (< 20) Submitted: 3/7/2018 6:03:49 PM : Outperform Start Price: $15.75 CORT Score: -0.69

Corcepts lead product korlym is expected to lose exclusivity in 2019.. although that seems concerning.. it isnt.. the small market size in CS will prevent price wars for when generics do enter into the market.. also, Relacorilant, an improved product for CS will EASILY replace Korlym.. Relacorilant will make korlym and any other generic competitors in the space absolete.. Relacorilant is also being explored in clinical trials in combination with abraxane for solid tumors.. Management has expressed that early results have been promising.. If solid tumor data results are as good as managements optimism, we can see CORT fly well above what it is currently worth.. Management are also exploring other combo therapies including korlym in TNBC, CORT125281+xtandi in CRPC.. Also CORT118335 for NASH shouldn't be taken out of the picture.. since their pipeline are all in early stages of development, CORT is considered a speculative play in the favor of longs. the preliminary data of Relacorilant is robust(despite low N) and was executed with the low-end dose.. a higher dose should prove to have better efficacy... Abraxane as a stand alone agent for solid tumors has shown to work in LC,TNBC, CRPC.. the problem with early clinical combo therapies(W/O single agent data), is that sometimes it is hard to figure out whether the net effect is from the combo or from the standalone agent. regardless this confusion of benefit from the combo should boost CORT's share price as market investors are incompetent of realizing the difference between solo efficacy vs combo efficacy.. (see nktr-214).

Recs

0
Member Avatar aeroberts831 (< 20) Submitted: 3/5/2018 9:18:29 PM : Outperform Start Price: $14.68 CORT Score: +6.05

Teva ANDA announcement of Corcept's lead product Korlym tanked stock 40%, but Teva will not bring to market a generic formulation of Korlym with any meaningful effect on Corcept's revenues.

Leaderboard

Find the members with the highest scoring picks in CORT.

Score Leader

thiscoloradokid

thiscoloradokid (< 20) Score: +782.72

The Score Leader is the player with the highest score across all their picks in CORT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
thiscoloradokid < 20 12/5/2012 12/4/2013 Outperform 3M $1.52 +863.16% +80.43% +782.72 0 Comment
alvojiggy 78.11 10/23/2013 Outperform 5Y $1.73 +746.24% +45.92% +700.32 0 Comment
GOGCwatch07 < 20 9/18/2013 Outperform 5Y $1.73 +746.24% +49.16% +697.08 0 Comment
wgrohman < 20 3/21/2013 Outperform 3Y $1.94 +654.64% +64.82% +589.82 0 Comment
FinanceGuy58 58.39 12/9/2013 7/24/2015 Outperform 3Y $2.01 +630.17% +40.73% +589.45 0 Comment
loangolfer < 20 1/10/2013 12/18/2017 Outperform NS $1.96 +646.56% +73.95% +572.61 0 Comment
HoosierDoozer 32.86 12/5/2013 Outperform 5Y $2.06 +610.68% +42.18% +568.50 0 Comment
HoldThatWinner 30.39 3/11/2013 Outperform 1Y $2.00 +632.00% +64.22% +567.78 0 Comment
cavemantrader 23.44 11/29/2013 Outperform 5Y $2.10 +597.14% +40.68% +556.46 1 Comment
rserafini 72.04 3/25/2013 Outperform 5Y $2.04 +617.65% +63.50% +554.14 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCantorFitz 39.78 12/12/2018 Outperform NS $18.61 -21.33% -4.63% -16.70 0 Comment
TrackPiperJaff 87.29 3/11/2015 Outperform NS $3.95 +270.63% +24.25% +246.38 0 Comment
TrackCreditSuiss 88.66 11/13/2012 Outperform NS $1.35 +25.93% +23.19% +2.74 8/9/2013 @ $1.70 0 Comment
TrackJMP 84.89 2/21/2012 Outperform NS $4.60 +218.26% +86.43% +131.83 0 Comment
TrackBioLogicEqu < 20 1/5/2012 Underperform NS $3.38 +333.14% +100.83% -232.30 0 Comment
TrackLadenburg < 20 1/6/2010 Outperform NS $2.99 +389.63% +124.70% +264.93 0 Comment
TrackTWeisel 88.79 8/15/2006 Outperform NS $3.69 -100.00% +1.93% -101.93 8/25/2006 @ $0.00 0 Comment

Advertisement